advertisement
Abstract #28229 Published in IGR 13-1
Therapeutic potential of new hydrogen sulfide-releasing hybrids
Sparatore A; Santus G; Giustarini D; Rossi R; Del Soldato PExpert Review of Clinical Pharmacology 2011; 4: 109-121
A new class of hydrogen sulfide (H(2)S)-donating hybrids combined with pharmacologically active compounds is presented in this article. The pharmacological profiles of some hybrid lead compounds in the areas of inflammation, H(2)S-donating diclofenac (ACS 15); cardiovascular, H(2)S-donating aspirin (ACS 14); urology, H(2)S-donating sildenafil (ACS 6); and neurodegenerative, H(2)S-donating latanoprost (ACS 67) for glaucoma treatment and H(2)S-donating levodopa (ACS 84) for Parkinsons disease, are described. The new H(2)S-releasing hybrids demonstrate remarkable improvement in activity and tolerability as compared with the related parent compounds, suggesting an active pharmacological role for H(2)S. Finally the mechanism(s) of action of glutathione-dependent and independent, and of gas (H(2)S) release (spontaneous or enzymatic) and its implications for clinical pharmacology perspectives will be also discussed.
A. Sparatore. Department of Pharmaceutical Science Pietro Pratesi, Universit Degli Studi di Milano, Via Mangiagalli, 25-20133 Milano, Italy. anna.sparatore@unimi.it
Classification:
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)
11.8 Neuroprotection (Part of: 11 Medical treatment)
